NCT01213355 - Scopolamine Challenge Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Healthy

Interventions

DRUG

Placebo

Capsule, single dose, oral, 1 day

DRUG

Scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

5 mg, PF-05212377, capsule, single dose, 1 day

DRUG

Scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

20 mg, capsule PF-05212377, single dose, 1 day

DRUG

scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

60 mg PF-05212377, capsule, single dose, 1 day

DRUG

scopolamine

injectable sub cutaneous formulation, single dose, 1 day

DRUG

Donepezil

Tablet, 10mg, single dose, 1 day

DRUG

Scopolamine

injectable sub cutaneous formulation, single dose, 1 day

Trial Locations (1)

Pfizer Investigational Site, Rennes